Background: Prediabetes often occurs together with dyslipidaemia, which is paradoxically
PR D ) were compared with the nonprediabetic control group. No pathways were upregulated or downregulated when the PR D group was compared with the C 0 group. Five genes in the PR 0 group and 1 in the PR D group were significantly differentially expressed in comparison with the C 0 group.
Conclusions: Blood cell gene expression profiles differ significantly between prediabetic subjects with and without dyslipidaemia. Whether this classification may be used in detection of prediabetic individuals at a high risk of cardiovascular complications remains to be examined. 1 Deficiency in the insulin secretion of pancreatic beta cells has a more pronounced role in PR than insulin resistance, 2 but most persons with PR are also insulin-resistant. 3 Dyslipidaemia, which is defined by elevated total cholesterol (TC), low density lipoprotein (LDL) cholesterol (LDL-C), nonhigh density lipoprotein cholesterol (non-HDL-C) or triglycerides (TGs), or low HDL-C, 4 commonly occurs together with T2DM. A typical pattern of lipid abnormalities in diabetic patients includes hypertriglyceridaemia, low HDL-C, and a presence of small dense LDL-C particles. 5 The same pattern, known as atherogenic dyslipidaemia, has been shown to occur already during the prediabetic stage. 6, 7 Metabolically, low absorption efficiency and high synthesis of cholesterol are also related to an elevated serum glucose level and insulin resistance. 8, 9 However, whether the progression or development of CV complications will differ in prediabetic patients with and without dyslipidaemia is not well known.
In atherogenic dyslipidaemia, statins are widely used as first-line drugs. Because the treatment goal for serum LDL-C is more stringent in patients with T2DM than in those without T2DM, high-dose statin treatment may be needed. 4 The use of statins in prediabetic subjects may be complicated because these drugs can increase the risk of incident T2DM, 10 and by affecting insulin sensitivity, insulin secretion and glucose transport increase plasma glucose levels. 11 Despite this controversy, statins yield an overall benefit in preventing vascular events, and therefore, these drugs are widely recommended in current treatment guidelines also for the treatment of dyslipidaemia in T2DM patients. 4 With this clinical background, it is rational to seek better understanding of the metabolic differences of PR subphenotypes with and without dyslipidaemia.
Gene expression and pathway profiling of blood and tissue samples may provide better understanding of the pathogenesis of PR and its association to dyslipidaemia. An earlier metabolomic investigation of plasma from nondiabetic subjects with reduced insulin sensitivity showed alterations in lipid metabolic pathways, steroid hormone biosynthesis, and bile acid metabolism. 12 Most of these pathways and certain amino acid metabolism pathways have also been found to be differentially regulated in the liver of pigs with impaired incretin (a group of metabolic hormones that stimulate a decrease in blood glucose levels) function. 13 Altered pathways in lipid metabolism, insulin action, inflammatory response, and complex oxidative processes have also been revealed from subcutaneous adipose and muscle tissue from nondiabetic, insulin-resistant subjects. 14, 15 However, these earlier metabolic studies did not take into account whether plasma lipid abnormalities were present in the subjects.
It has been suggested that insulin resistance elicits dyslipidaemia either mechanically or by means of genetic linkage, but further validation is still needed. 2, 3 We aimed to identify the metabolic pathways and gene expression associated with the prediabetic state, with special respect to a division based on the subjects' dyslipidaemia status. To pinpoint dysregulated metabolic pathways associated with these PR subphenotypes, we performed a gene set enrichment analysis (GSEA) and also otherwise analysed gene-wise differences between PR subphenotypes and controls.
| MATERIALS AND METHODS

| Population
The Cardiovascular Risk in Young Finns Study (YFS) is a Finnish longitudinal population study on the evolution of CV risk factors from childhood to adulthood; the sample and methods have been described in detail elsewhere. 16, 17 The present study included 1240 subjects who
were not diagnosed with T1DM or T2DM (in 2012), were not on medication for hypertension or hypercholesterolaemia, and for whom complete gene expression data as well as data on lipids, glucose, and clinical characteristics were available.
The study plan was approved by the ethics committees of all participating universities, and the study protocol of each study phase corresponded with the proposal by the World Health Organization.
All subjects gave written informed consent, and the study was conducted in accordance with the Declaration of Helsinki.
| Clinical and biochemical measurements
Height and weight were measured, and body mass index (BMI) was calculated as weight in kilograms divided by height in metres squared.
Waist circumference was measured by using an anthropometric tape at the midpoint between the iliac crest and the lowest rib to the nearest 0.1 cm. Blood pressure was measured 3 times after a 5 minute rest with a random zero sphygmomanometer and was estimated as the average of the 3 measurements.
Venous blood samples were drawn after an overnight fast for the determination of serum lipid levels, glucose, insulin, glycated haemoglobin A1c (HbA1c), and high-sensitive C-reactive protein (hs-CRP Dyslipidaemia was defined according to the European guidelines. 4 The criteria for dyslipidaemia were TC greater than 5.0 mmol/L, LDL-C greater than 3.0 mmol/L, HDL-C less than 1.0 mmol/L in men and less than 1.2 mmol/L in women, non-HDL-C greater than 3.8 mmol/L, or TG greater than 1.7 mmol/L.
| Statistical analysis
Gene sets were collected from 5 publicly available collections: BioCarta Potential population stratification was taken into account by using principal components (PCs) computed from all genotypes as covariates. 21 Based on a scree plot, the 7 first PCs were used. In addition to the PCs, the analyses were adjusted by age, sex, BMI or waist circumference, smoking, insulin, systolic and diastolic blood pressure, and hs-CRP. R language was used for adjusting the gene expression data. After the adjustment, GSEA software (http://www.
broad.mit.edu/gsea) 22, 23 was used to analyse the association of gene pathways with the phenotype. The pathways were considered to be significantly upregulated or downregulated when the false discovery rate (FDR) was smaller than 0.10 and the family-wise error rate (FWER) was smaller than 0.05 after 1000 permutation cycles. False discovery rate less than 0.25 can be considered significant according to the criteria recommended by Subramanian et al. 22 The expression of individual genes in the same setting was analysed by using the phenoTest R package with a Benjamini-Hochberg-FDRcorrected P value of less than or equal to .05 and log2 fold change of greater than or equal to 1.5 as the significance level. The analysis was adjusted with age, sex, BMI, and the first 7 PCs. For box plots, the statistical significance of the difference in gene expression was assessed by using the nonparametric Wilcoxon signed-rank test.
| RESULTS
The demographics of the study population, when the division is based on any type of dyslipidaemia, or hypercholesterolaemia defined as a high LDL-C (LDL > 3.0 mmol/L) only, are presented in Table 1 . Of the nonmedicated subjects with PR, 79.5% had dyslipidaemia and 66.0% hypercholesterolaemia defined as LDL greater than 3.0 mmol/L. When comparing all PR individuals to the nonprediabetic control group (C), GSEA identified upregulation of cholesterol biosynthesis pathways in all of the used but differently adjusted models 1 to 3 (FDR < 0.014 for all) ( Table 2) . A positive normalized enrichment score (NES)
indicated that all the pathways were upregulated. The leading-edge subsets containing the most upregulated genes are almost identical in the KEGG steroid and HumanCyc cholesterol biosynthesis pathways (Table SS1 ). In the PR versus C group comparison, superpathway of methionine degradation remained significantly enriched in models 1 and 2 (FDR < 0.006 and <0.015, respectively). However, in model 3, the additional adjustment with hs-CRP abolished the association.
Two additional pathways, cholesterol biosynthesis II (via 24,25-dihydrolanosterol) and cholesterol biosynthesis III (via desmosterol) from HumanCyc, were closely and significantly co-enriched with the cholesterol biosynthesis pathway because they all share the same genes. Hence, they are not shown in the tables.
These KEGG and HumanCyc pathways were also upregulated when the PR 0 group was compared with the corresponding control group without PR and dyslipidaemia (C 0 ) after adjustment for age, sex, BMI, and the first 7 PCs (Table 3 ). In addition, in this setting, the pathways for interleukin-12 (IL12)-mediated signalling events and downstream signalling in naive CD8+ T-cells were also significantly (Table 4 ). In prediabetic subjects with high LDL-C (≥3.0 mmol/L) (PR HC ), no pathways were significantly The expression of individual pathway genes was not statistically significant in any PR phenotype when compared with the C 0 group. This is explained by the fact that GSEA considers all expressed genes by rank without a fold-change threshold. Therefore, we also tested gene-wise differences between PR subphenotype groups with a less stringent cut-off value for log2 fold change (>1.2) and a BenjaminiHochberg-FDR-corrected P value of less than or equal to .05 (Table   S2 ). In gene-wise analysis, we identified 5 genes upregulated in the 
| DISCUSSION
Our analysis of peripheral blood cell mRNA expression shows, for the first time, that the pathway profiles differ significantly between prediabetic subphenotypes with and without dyslipidaemia. We observed that, compared with normoglycaemic and normolipidaemic controls, the cholesterol biosynthesis pathway was upregulated in normolipidaemic prediabetic individuals but not in those with both PR and dyslipidaemia. Also, pathways related to the immune response were upregulated only in the PR 0 group. It is not surprising that pathway analysis identified differences between prediabetic subphenotypes. However, using the most recent pathway databases, our analysis pinpointed the specific pathways that were upregulated.
The enrichment of the cholesterol biosynthesis pathway was independent of both BMI and waist circumference. Parallel results have been reported by Gylling et al, 9 who assayed cholesterol precursors and markers of cholesterol synthesis and absorption from plasma. In their study, markers of cholesterol synthesis were already increased in subjects with IFG and cholesterol metabolism was regulated more by peripheral insulin sensitivity than obesity. In the present study, the enrichment remained significant until the analysis was adjusted for hs-CRP. This suggests that an upregulated cholesterol biosynthesis pathway is related to the increased overall inflammation as measured by hs-CRP. Interestingly, serum hs-CRP concentration has been previously associated with dietary cholesterol absorption but not synthesis of cholesterol in subjects with IFG or IGT and features of the metabolic syndrome cholesterol metabolism. 24 The mechanism through which PR in the absence of dyslipidaemia 1 study has demonstrated that the mechanisms that regulate gene expression in liver and mononuclear leukocytes are similar and that these leukocytes can be used to predict the level of expression of HMGCR and LDL receptor genes. 30 This could indicate that the hepatic cholesterol production is also increased in the PR 0 group, although we did not observe increased expression of these 2 genes.
Recent data suggest that nonalcoholic fatty liver disease (NAFLD) results mainly from disturbed hepatic cholesterol homeostasis and the hepatic accumulation of free cholesterol. 31 If the cholesterol synthesis pathway is upregulated in the liver, the newly synthesized cholesterol may promote the pathogenesis of NAFLD because cholesterol export and bile acid synthesis pathways were not upregulated. This hypothesis is supported by a Japanese study that showed a positive association between NAFLD and IFG, independently of T2DM risk factors.
32
Nonalcoholic fatty liver disease is also considered to be a consequence of insulin resistance, 33 but it is also an independent risk factor of T2DM, particularly in individuals with IFG. 34 Based on above reasons, potentially increased hepatic cholesterol production would imply that the onset of PR launches a cascade leading to hypercholesterolaemia and/or NAFLD, which highlights the importance of early detection of PR and prevention of T2DM through lifestyle intervention. Guidelines in condensed form have been provided for building up an effective intervention programme; the IMAGE toolkit 35 also gives instructions for evaluation and quality assurance. In addition to working at the patient level, actions at policy and environmental levels are needed for sustainable diabetes prevention. 36 The enrichment of the IL12 signalling pathway remained significant in all models when the PR 0 group was compared with the C 0 group. Elevated IL12 levels have been previously shown to be dependent on hs-CRP 37 and peripheral insulin resistance 38 in T2DM.
Because the IL12 pathway remained upregulated when the analysis was adjusted with both serum insulin level and hs-CRP, it may be suggested that, in the PR 0 group, the activation of the IL12 pathway is mediated by another mechanism. When only the LDL-C levels were taken into account, the pathway profiles were similar to the ones of all prediabetic subjects, ie, when the dyslipidaemia status was not considered. This suggests that the upregulation of IL12-mediated and CD8+ T-cell pathways could be partly related to hypertriglyceridaemia or low HDL-C.
The enrichment of cholesterol biosynthesis and inflammationrelated pathways was seen in the PR 0 group when compared with the C 0 group but not when compared with the PR D group, which implies that the metabolic differences between the 2 PR subphenotypes are small. However, whether this difference will evolve over time requires longitudinal studies.
The analysis of individual genes revealed only a moderate increase in gene expression. Some of the genes have been previously associated with metabolic dysfunction. Only one gene, SLPI, which is a potent inhibitor of the inflammatory cascade, 39 was upregulated in the PR D group. The upregulation of SLPI has also been previously shown to correlate negatively with HDL-C and positively with HbA1c.
This may be due to an attempt to counterbalance the low-grade inflammation associated with PR and dyslipidaemia. 40 The expression of LDL receptor or scavenger receptor genes 41 plaques, 42 our results imply that PR combined with dyslipidaemia does not directly cause atherosclerosis, which is also stated by Grundy. 2 Three of 5 genes that were slightly upregulated in the PR 0 group-GZMB, PRF1, and KIR2DL4-have been found to be downregulated after exposure to high blood glucose in normoglycaemic controls. In T2DM patients, the expression levels of these genes have been reported to be low already and hardly affected by hyperglycaemia. 43 These genes are typically expressed in cells with cytotoxic functions, such as CD8+
T-cells. 44 Granzyme B and PRF1 are also included in the downstream signalling in the naive CD8+ T-cell pathway, which was upregulated in the PR 0 group but not in the PR D group in comparison with the C 0 group. The reason why GZMB, PRF1, and KIR2DL4 were upregulated in the PR 0 group but not in the PR D group and expressed in lower levels in T2DM patients in the study by van der Pouw Kraan et al 43 might be that 1 or more of the components of dyslipidaemia co-regulate the expression of these genes; the T2DM patients in their study 43 met the elevated TG criterion of dyslipidaemia used in our study. However, in another study, the plasma level of granzyme B correlated positively with fasting glucose and HbA1c, as well as with TGs, TC, and LDL-C. 45 The present study has some limitations. A major one is that profiling gene expression from peripheral blood cells makes it challenging to speculate how the expression levels represent the gene expression in other tissues. Another limitation is that no glucose tolerance tests were performed on the study population and the definition of PR was based only on fasting plasma glucose and HbA1c levels. Some studies, 46, 47 but not all, 48 have shown that IGT is a better predictor of CV complications than IFG. This raises the question whether there are differences in gene expression and pathway profiles when PR is diagnosed by either IFG or IGT. However, the HbA1c cut-off point for PR has a high specificity to identify cases of IGT 1 and also subsequent 6 year diabetes incidence. 49 In addition, the Finnish gene pool has been shown to be distinctive and the results may not be directly generalizable to populations with a different ethnic background. We also recognize that microarray studies are limited by multiple testing problems and false positives.
In summary, our data indicate that blood cell gene expression pathway profiles differ significantly between prediabetic subphenotypes with and without dyslipidaemia. The pathway analysis identified upregulated pathways, including cholesterol biosynthesis, IL12-mediated signalling, and signalling in naïve CD8+ T-cells in prediabetic individuals only in the absence of dyslipidaemia. However, whether this classification may be used in, eg, early-phase detection of individuals at a high risk of CV complications, should be further examined in longitudinal studies.
The clinical implication is that physicians should actively screen patients for PR and dyslipidaemia and encourage especially those with PR to permanent lifestyle changes with active follow-ups.
